- Home
- ABP vs ALXO Comparison
ABP vs ALXO Comparison
Compare ABP & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABP
- ALXO
- Stock Information
- Founded
- ABP 2004
- ALXO 2015
- Country
- ABP United States
- ALXO United States
- Employees
- ABP N/A
- ALXO N/A
- Industry
- ABP Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ABP Health Care
- ALXO Health Care
- Exchange
- ABP Nasdaq
- ALXO Nasdaq
- Market Cap
- ABP 76.2M
- ALXO 76.5M
- IPO Year
- ABP N/A
- ALXO 2020
- Fundamental
- Price
- ABP $1.30
- ALXO $1.74
- Analyst Decision
- ABP
- ALXO Buy
- Analyst Count
- ABP 0
- ALXO 6
- Target Price
- ABP N/A
- ALXO $11.00
- AVG Volume (30 Days)
- ABP 2.1M
- ALXO 1.1M
- Earning Date
- ABP 02-18-2025
- ALXO 03-06-2025
- Dividend Yield
- ABP N/A
- ALXO N/A
- EPS Growth
- ABP N/A
- ALXO N/A
- EPS
- ABP N/A
- ALXO N/A
- Revenue
- ABP $122,000.00
- ALXO N/A
- Revenue This Year
- ABP N/A
- ALXO N/A
- Revenue Next Year
- ABP N/A
- ALXO N/A
- P/E Ratio
- ABP N/A
- ALXO N/A
- Revenue Growth
- ABP N/A
- ALXO N/A
- 52 Week Low
- ABP $0.95
- ALXO $1.19
- 52 Week High
- ABP $13.00
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- ABP N/A
- ALXO 53.13
- Support Level
- ABP N/A
- ALXO $1.56
- Resistance Level
- ABP N/A
- ALXO $1.94
- Average True Range (ATR)
- ABP 0.00
- ALXO 0.16
- MACD
- ABP 0.00
- ALXO -0.01
- Stochastic Oscillator
- ABP 0.00
- ALXO 50.00
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.